Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.47), $0.07 better than the analyst estimate of ($0.54). Revenue for the quarter came in at $221.9 million versus the consensus estimate of $205.63 million.

GUIDANCE:

Tandem Diabetes sees FY2024 revenue of $885-892 million, versus the consensus of $868.6 million. And $222 million to $225 million in the third quarter, versus the consensus of $220.4 million.
Non-GAAP gross margin is estimated to be approximately 51 percent for the full year and the third quarter.
Adjusted EBITDA margin is estimated to be breakeven as a percent of sales for the full year and the third quarter.
Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $120 million. This includes:

Approximately $100 million non-cash, stock-based compensation expense.
Approximately $20 million depreciation and amortization expense.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.